The Immune Landscape of Cancer.

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Yang THO, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Nam Sy Vo , Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CE, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich L (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Book Volume: 48

Pages Range: 812-830.e14

Journal Issue: 4

DOI: 10.1016/j.immuni.2018.03.023

Abstract

We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across cancer types, we identified six immune subtypes-wound healing, IFN-γ dominant, inflammatory, lymphocyte depleted, immunologically quiet, and TGF-β dominant-characterized by differences in macrophage or lymphocyte signatures, Th1:Th2 cell ratio, extent of intratumoral heterogeneity, aneuploidy, extent of neoantigen load, overall cell proliferation, expression of immunomodulatory genes, and prognosis. Specific driver mutations correlated with lower (CTNNB1, NRAS, or IDH1) or higher (BRAF, TP53, or CASP8) leukocyte levels across all cancers. Multiple control modalities of the intracellular and extracellular networks (transcription, microRNAs, copy number, and epigenetic processes) were involved in tumor-immune cell interactions, both across and within immune subtypes. Our immunogenomics pipeline to characterize these heterogeneous tumors and the resulting data are intended to serve as a resource for future targeted studies to further advance the field.

Involved external institutions

Institute for Systems Biology United States (USA) (US) British Columbia Cancer Agency Canada (CA) University of California San Francisco (UCSF) United States (USA) (US) University of North Carolina at Chapel Hill United States (USA) (US) Columbia University United States (USA) (US) Barcelona Supercomputing Center / Centro Nacional de Supercomputación Spain (ES) Massachusetts Institute of Technology (MIT) United States (USA) (US) Sage Bionetworks United States (USA) (US) Dana–Farber Cancer Institute United States (USA) (US) Columbia University Irving Medical Center (CUIMC) United States (USA) (US) Johns Hopkins University (JHU) United States (USA) (US) Stanford University United States (USA) (US) Seven Bridges Genomics United States (USA) (US) University of Calgary Canada (CA) Vrije Universiteit Brussel (VUB) Belgium (BE) University of Texas MD Anderson Cancer Center United States (USA) (US) Chan Soon-Shiong Medical Center at Windber United States (USA) (US) Medical College of Wisconsin (MCW) United States (USA) (US) Sidra Medical and Research Center Qatar (QA) Cold Spring Harbor Laboratory United States (USA) (US) Henry Ford Health System (HFHS) United States (USA) (US) University of Alabama at Birmingham (UAB) United States (USA) (US) Van Andel Institute United States (USA) (US) Stony Brook Medicine United States (USA) (US) National Cancer Institute (NCI) United States (USA) (US) Mount Sinai Hospital (MSH) Canada (CA) University of Washington United States (USA) (US)

How to cite

APA:

Thorsson, V., Gibbs, D.L., Brown, S.D., Wolf, D., Bortone, D.S., Yang, T.-H.O.,... Shmulevich, L. (2018). The Immune Landscape of Cancer. Immunity, 48(4), 812-830.e14. https://doi.org/10.1016/j.immuni.2018.03.023

MLA:

Thorsson, Vesteinn, et al. "The Immune Landscape of Cancer." Immunity 48.4 (2018): 812-830.e14.

BibTeX: Download